Tests GR1803 injection in people with systemic lupus erythematosus
Tests the GR1803 injection in adults with systemic lupus erythematosus, an autoimmune disease.
Plain-language title generated from the registry record
Registry title: A Study of GR1803 in Systemic Lupus Erythematosus
Key facts
- Where
- Wuhan, ChinaSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07348055, who can take part
Where in China
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Trial code
- NCT07348055
- Record updated
- 10 March 2026
- Original description
to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosusRead full original descriptionShow less
A Phase Ib/IIa Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of GR1803 Injection in Subjects With Systemic Lupus Erythematosus
to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus
Inclusion: comfirmed diagnosis of systemic lupus erythematosus; SLEDAI-2K≥6分; written informed consent and ability to comply with protocol requirements; have received adequate dose of glucocorticoids, antimalarials, immunosuppressants for 3 months.
Exclusion: with unstable acute and chronic diseases; active infection; history of malignant tumor within 5 years.